The case for & against
Bull & Bear analysis
Bearish
Myomo, Inc. (NASDAQ: MYO) operates within the innovative medical device sector, specifically focusing on advanced robotic solutions for individuals suffering from upper extremity paralysis. Through its flagship product, MyoPro, Myomo aims to restore mobility using powered orthoses, positioning itself as a leader in enhancing rehabilitation technologies. With a significant emphasis on navigating the complex healthcare reimbursement landscape, Myomo is poised for expansion as it capitalizes on substantial demand in underserved demographics.
Bull says
- ↑Q1 2026 revenue reached $10.1 M, a 3% year-over-year increase
- ↑Recurring patient revenue climbed from 25% to 49% of Q1 sales
- ↑Covered lives expanded from 9 M to 158 M via new payer contracts
- ↑International revenue surged 53% in Q1, driven by Germany growth
- ↑Gross margin improved to 68.2% in Q1 2026
- ↑MyoPro 2X launch and new mobile app to boost patient engagement
Bear says
- ↓Q1 2026 net loss narrowed to $3 M but operating expenses rose 64% YoY
- ↓Average selling price of $58.8 K likely to decline on channel mix shifts
- ↓Negative earnings yield and low profitability factors signal margin pressure
- ↓High Medicare Advantage denial rates threaten stable reimbursement
- ↓Increased marketing spend and operational costs elevate cash-burn risks
- ↓Competitive and regulatory pressures may further compress pricing
Investment themes with MYO
Health Care Equipment & Supplies↑ +0.40%
Clinical instruments and devices powering patient care
ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-11-2026bullish
Transcript signals
Bull points
- Our revenue for the first quarter of 2026 was $10.1 million, up 3% versus the prior year period, driven by a higher average selling price, or ASP, which was $58,800, up 9% due to higher Medicare Part B and Medicare Advantage reimbursement amounts and a positive channel mix.
- Revenue from recurring patient sources represented 49% of first quarter revenue, up from 25% in the prior year, marking significant progress in shifting towards recurring patient sources at a lower patient acquisition cost.
- Gross margin for the first quarter of 2026 was 68.2%, up from 67.2% a year ago, driven by a higher ASP and material cost reductions, partially offset by higher labor and travel costs needed to fit patients on site.
Bear points
- As many healthcare providers are seeing, the macro environment for Medicare Advantage plans continues to be challenging. To mitigate the impact, we are focusing on in-network patients obtained through our contracting efforts, where early results are showing higher authorization rates compared with non-contracted payers.
- I do expect that the ASP will come down a bit due to channel mix in the second quarter, and I think it's still prudent to assume maybe around a, you know, a $55,000 or so ASP on a more, you know, longer-term basis.
Read full transcript analysis ›